Lumipulse® G pTau 181
Immunoreaction cartridges for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative measurement of Tau phosphorylated at threonine 181 (pTau 181) in human cerebrospinal fluid (CSF).
This CSF biomarker is intended to be used as an aid for diagnosis in patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline.
The CSF biomarker supports the probability of AD pathology only as an adjunct to other diagnostic evaluations.
Product number 230350
Product number 230367
Powered by Bioz
-
Citations
-
Documentation
Browse regulatory documents for this product
Create a (free!) eServices account and start browsing all product documentation right away.
Get access to this section and more
Create a free eServices account now and instantly access multiple digital resources:
- Product documentation
- Selected scientific posters
- Product leaflets
- How-to videos and more…
-
Insights
Feb 20, 2024Publication - Serum and cerebrospinal fluid neurofilament light chains measured by SIMOA™, Ella™, and Lumipulse™ in multiple sclerosis naïve patients
We would like to draw your attention to a first publication on our Lumipulse® G NfL solution. In this article you will find a method comparison of CSF...
Dec 1, 2023CTAD 2023 – Spotlight on recent advances in blood-based biomarkers for Alzheimer’s disease
Both fluid and imaging biomarkers provide biological evidence for the underlying etiology of cognitive impairment. The core fluid biomarkers of...
Jul 10, 2023IVDR status update for Fujirebio’s Neuro products
The European CE-marking is used to support registrations of in vitro diagnostic (IVD) medical devices in many jurisdictions around the world. The...
-
Product inquiry
-
Related products
